Roche Archives -

Genentech, a member of the Roche Group, has announced that it is voluntarily withdrawing the US indication of

Genentech withdraws US indication of Tecentriq for bladder, urinary tract cancer

https://pharmaphorum.com/news/genentech-withdraws-us-indication-of-tecentriq-for-bladder-urinary-tract-cancer/

Genomic testing ‘should be offered to all cancer patients in Scotland’

Phil Taylor AstraZeneca, Eli Lilly, genomics, NHS, Novartis, Oncology, patients, precision medicine, Roche, Scotland 0 Comment

A group representing pharma companies selling precision therapies for cancer has called for a change to the way

Genomic testing ‘should be offered to all cancer patients in Scotland’

https://pharmaphorum.com/news/genomic-testing-should-be-offered-to-all-cancer-patients-in-scotland/

Deep Dive/ Patients/ Views & Analysis/ Views and analysis

The future of clinical research in neurology must be driven by community voices

mike.hammerton@pharmaphorum.com Caroline Averius, Christine Eighteen, Deep Dive, Deep Dive: Patients and Partnerships, Jannice Roeser, Patients and Partnerships, Roche, Stephanie Ludwig 0 Comment

Strong patient partnerships are more important than ever. In the pursuit of a personalised future for neurological care,

The future of clinical research in neurology must be driven by community voices

https://pharmaphorum.com/patients/the-future-of-clinical-research-in-neurology-must-be-driven-by-community-voices/

Cancer/ News/ News/ News/ Oncology/ R&D

ImmunoGen ELAHERE wins accelerated FDA approval for ovarian cancer

Nicole Raleigh ELAHERE, FDA accelerated approval, FOLR1, gynaecological cancer, immunogen, MIRASOL, Oncology, ovarian cancer, platinum-resistant, Roche 0 Comment

ImmunoGen, Inc. has announced that its platinum-resistant ovarian cancer drug ELAHERE (mirvetuximab soravtansine-gynx) has been granted FDA accelerated

ImmunoGen ELAHERE wins accelerated FDA approval for ovarian cancer

https://pharmaphorum.com/news/immunogen-elahere-wins-accelerated-fda-approval-for-ovarian-cancer/

News/ News/ News/ Oncology/ R&D

Roche deepens ties with Jnana with a second licensing deal

Phil Taylor financing, Immunology and inflammation, Jnana Therapeutics, neurology, Oncology, partnering, Roche 0 Comment

Swiss pharma group Roche has doubled down on a partnership with Jnana Therapeutics, paying $50 million upfront to

Roche deepens ties with Jnana with a second licensing deal

https://pharmaphorum.com/news/roche-deepens-ties-with-jnana-with-a-second-licensing-deal/

News/ News/ R&D

Alzheimer’s treatment hopes take another dive as Roche drug fails trial

Phil Taylor Alzheimer's disease, amyloid, Biogen, Eisai, gantenerumab, Genentech, lecanemab, neurology, Roche 0 Comment

Roche’s Genentech division has reported disappointing top-line results from its highly-anticipated phase 3 trial of gantenerumab in early

Alzheimer’s treatment hopes take another dive as Roche drug fails trial

https://pharmaphorum.com/news/alzheimers-treatment-hopes-take-another-dive-as-roche-drug-fails-trial/

Radiology technician examens mammography test

News/ News/ News/ Oncology/ R&D

After setbacks for Roche and Sanofi, AZ scores oral SERD win

Phil Taylor amcenestrant, AstraZeneca, breast cancer, camizestrant, elacestrant, giridestrant, Menarini Group, Oncology, Radius Health, Roche, Sanofi, serd 0 Comment

AstraZeneca seems to have dodged the problems besetting other developers of oral selective oestrogen receptor degrader (SERD) drugs

After setbacks for Roche and Sanofi, AZ scores oral SERD win

https://pharmaphorum.com/news/after-setbacks-for-roche-and-sanofi-az-scores-oral-serd-win/

News/ News/ Sales and Marketing

Roche Q3 results show steep fall-off in COVID product sales

Phil Taylor COVID-19, Evrysdi, Financial, Hemlibra, Ocrevus, Phesgo, Roche, Vabysmo 0 Comment

Roche’s third-quarter results have revealed a clear sign that the bumper sales boosting companies that have provided products

Roche Q3 results show steep fall-off in COVID product sales

https://pharmaphorum.com/news/roche-q3-results-show-steep-fall-off-in-covid-product-sales/

Cancer/ News/ News/ News/ Oncology/ R&D

Roche gets FDA approval for HER2 breast cancer diagnostic

Nicole Raleigh AstraZeneca, breast cancer, Daiichi, Enhertu, FDA approval, her2, Roche 0 Comment

The FDA has approved Swiss pharmaceutical company Roche’s first companion diagnostic for identifying those patients with HER2 low-metastatic

Roche gets FDA approval for HER2 breast cancer diagnostic

https://pharmaphorum.com/news/roche-gets-fda-approval-for-her2-breast-cancer-diagnostic/

Trending

Roche

Login